<!DOCTYPE html>

<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta content="IE=edge" http-equiv="X-UA-Compatible" />
    <meta content="width=device-width, initial-scale=1.0" name="viewport" />
    <title>GA TB Reference Guide</title>
    <meta content="GA TB Reference Guide" name="description" />
    <meta content="SitePoint" name="author" />
    <link href="../assets/uikit.css" rel="stylesheet" />
    <link href="../assets/style.css" rel="stylesheet" />
  </head>

  <body>
    <div class="uk-container">
      <div class="chapter-header">
        <div class="header-title">
          <div>
            <img
              src="ic_chart.svg"
              width="16"
              height="16"
              class="ic_chapter_icon"
            />
          </div>
          <p class="chapter-title">
            15. Summary of Recommendations for Treatment of Active TB Disease in
            Persons with HIV
          </p>
        </div>
        <p class="last-updated"><i>Last Updated June 2024</i></p>
      </div>
      <hr />
      <div
        class="uk-overflow-auto"
        id="table_15_summary_of_recommendations_for_treatment_of_active_tb_disease_in_persons_with_hiv"
      >
        <div class="uk-tabs-container">
          <ul class="tabs">
            <li>
              <button class="tab active-tab" onclick="switchTab(0, event)">
                When to start ART
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(1, event)">
                How to prevent IRIS in TB/HIV
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(2, event)">
                TB regimen: DS-TB
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(3, event)">
                CoreART principles with rifamycins
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(4, event)">
                INSTIs with rifamycin
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(5, event)">
                NNRTIs with rifampin
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(6, event)">
                Boosted PIs with rifampin
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(7, event)">
                NRTI backbone
              </button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(8, event)">TB-IRIS</button>
            </li>
            <li>
              <button class="tab" onclick="switchTab(9, event)">
                TB meningitis
              </button>
            </li>
          </ul>
        </div>

        <div
          id="option-content0"
          class="tab-content option-content active-option"
        >
          <p>
            <strong> When to start ART </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  <ul>
                    <li>
                      <strong>CD4 <50</strong>: start ART within
                      <strong>2 weeks</strong> of TB therapy
                    </li>
                    <li>
                      <strong>CD4 ≥50</strong>: start ART by
                      <strong>8–12 weeks</strong>.
                    </li>
                    <li>
                      <strong>TB meningitis</strong>: defer starting ART and
                      seek expert advice as CNS TB IRIS may increase morbidity
                      and mortality
                    </li>
                  </ul>
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  Early ART ↓ mortality. <br />
                  CNS TB early ART ↑ severe IRIS risk.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content1" class="tab-content option-content">
          <p>
            <strong> How to prevent IRIS in TB/HIV </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  <ul>
                    <li>
                      Consider prednisone <strong>40 mg/day</strong> for
                      <strong>2 weeks</strong>, then
                      <strong>20 mg/day</strong> for
                      <strong>2 weeks</strong> for patients with
                      <strong>CD4 ≤100</strong> who starting ART within 30 days
                      of TB treatment initiation and are responding well to TB
                      therapy.
                    </li>
                    <li>Consult with expert in TB/HIV.</li>
                  </ul>
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  Contraindicated for patients with rifampin-resistant TB,
                  Kaposi sarcoma, or active hepatitis B.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content2" class="tab-content option-content">
          <p>
            <strong> TB Regimen: Drug-susceptible TB (DS_TB) </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  Use standard <strong>6-month HRZE → HR</strong> regimen
                  (intensive phase 2 months HRZE, continuation phase 4-7 months
                  HR)
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>Remains the global standard for HIV-associated TB</td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content3" class="tab-content option-content">
          <p>
            <strong> Core ART principles with rifamycins </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  Rifamycins (rifampin, rifabutin, rifapentine) are the most
                  important TB drug in the treatment of DS-TB and every effort
                  should be made to include them in the treatment regimen.
                  However, rifamycins have many drug-drug interactions.
                  <span
                    class="info-icon"
                    data-tooltip="NOTE: Always consult a drug-drug interaction tool and/or an expert to assure correct medication and dose selection."
                    data-tooltip-position="tooltip-center"
                    >i</span
                  >
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  Rifamycins strongly induce CYP3A, UGT, P-gp, causing major ARV
                  interactions.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content4" class="tab-content option-content">
          <p>
            <strong> INSTIs with rifamycin </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  <strong>Dolutegravir (DTG)</strong>: Increase does to 50 mg
                  <strong>twice daily</strong> while on rifampin.
                  <strong>Bictegravir (BIC)</strong> (INSTI in Biktarvy) is
                  contraindicated with rifampin and other rifamycins.
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  <ul>
                    <li>DTG BID validated in HIV–TB.</li>
                    <li>BIC levels drop severely.</li>
                  </ul>
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content5" class="tab-content option-content">
          <p>
            <strong> NNRTIs with rifampin </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td><strong>Efavirenz 600 mg</strong> daily is compatible.</td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  Efavirenz generally maintained at therapeutic levels with
                  rifampin.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content6" class="tab-content option-content">
          <p>
            <strong> Boosted PIs with rifampin </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  <strong>Do NOT use rifampin</strong> with ritonavir- or
                  cobicistat-boosted PIs. Use <strong>rifabutin</strong> instead
                  of rifampin if PI required (can use with ritonavir, cannot use
                  with cobicistat).
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  <ul>
                    <li>Monitor for uveitis and neutropenia with rifabutin.</li>
                    <li>
                      Dose adjustment for rifabutin generally required; consult
                      with HIV/TB expert.
                    </li>
                  </ul>
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content7" class="tab-content option-content">
          <p>
            <strong> NRTI backbone </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  Use <strong>TDF/FTC</strong> (Truvada) or
                  <strong>3TC</strong>. General recommendations are to avoid
                  <strong>TAF</strong> (i.e., TAF/FTC [Descovy]) use with
                  rifamycins. However, TAF can be used with rifampin with
                  caution and close monitoring of virologic response per the
                  DHHS/NIH HIV treatment guidelines.
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  Rifamycins lower plasma TAF concentration, but intracellular
                  levels are preserved.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content8" class="tab-content option-content">
          <p>
            <strong> TB-IRIS </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  Continue ART. NSAIDs for mild IRIS.
                  <strong>Prednisone</strong> for moderate–severe IRIS.
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>
                  ART should NOT be stopped except in life-threatening IRIS.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div id="option-content9" class="tab-content option-content">
          <p>
            <strong> TB Meningitis </strong>
          </p>

          <table class="uk-table">
            <tbody>
              <tr>
                <th>What to do</th>
                <td>
                  Use adjunctive <strong>steroids</strong>. Delay start of ART.
                  Seek expert advice as CNS TB IRIS may increase morbidity and
                  mortality
                </td>
              </tr>
              <tr>
                <th>Key details/caveats</th>
                <td>Reduces mortality and CNS IRIS.</td>
              </tr>
            </tbody>
          </table>
        </div>

        <div>
          <p>Abbreviations:</p>
          <ul>
            <li>ART – Antiretroviral therapy</li>
            <li>ARV – Antiretroviral</li>
            <li>BIC – Bictegravir</li>
            <li>CNS – Central nervous system</li>
            <li>CYP3A / CYP3A4 – Major drug-metabolizing enzymes</li>
            <li>DS-TB – Drug-susceptible TB</li>
            <li>DTG – Dolutegravir</li>
            <li>EFV – Efavirenz</li>
            <li>FTC – Emtricitabine</li>
            <li>HRZE – TB intensive-phase regimen:</li>
            <li>H = Isoniazid</li>
            <li>R = Rifampin</li>
            <li>Z = Pyrazinamide</li>
            <li>E = Ethambutol</li>
            <li>IRIS – Immune reconstitution inflammatory syndrome</li>
            <li>INSTI – Integrase strand transfer inhibitor</li>
            <li>NNRTI – Non-nucleoside reverse transcriptase inhibitor</li>
            <li>
              NRTI – Nucleoside/nucleotide reverse transcriptase inhibitor
            </li>
            <li>PI – Protease inhibitor</li>
            <li>P-gp – P-glycoprotein (drug efflux transporter)</li>
            <li>RFB (or RIFB) – Rifabutin</li>
            <li>RPT – Rifapentine</li>
            <li>TAF – Tenofovir alafenamide</li>
            <li>TDF – Tenofovir disoproxil fumarate</li>
            <li>
              TB-IRIS – TB-associated immune reconstitution inflammatory
              syndrome
            </li>
            <li>
              UGT (UDP-glucuronosyltransferase): A liver enzyme family that
              metabolizes many drugs. Rifamycins induce UGT1A1, lowering levels
              of drugs like dolutegravir and bictegravir.
            </li>
          </ul>

          <p>Source:</p>
          <ul>
            <li>
              A useful resource is the University of Liverpool HIV Drug
              Interactions tracker. Available at
              <a
                href="https://www.hiv-druginteractions.org/?utm_source=chatgpt.com"
                >https://www.hiv-druginteractions.org/?utm_source=chatgpt.com</a
              >
            </li>
            <li>
              Updated guidelines on treatment of active TB in persons with HIV
              and guidelines for dosage adjustments is available at the
              following website:
              <a
                href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-tuberculosis-hiv"
                >https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-tuberculosis-hiv</a
              >
            </li>
          </ul>
        </div>
      </div>
    </div>
  </body>
  <script src="../assets/uikit.js" type="text/javascript"></script>
  <script src="../assets/uikit-icons.js" type="text/javascript"></script>
  <script src="main.js" type="text/javascript"></script>
  <script>
    document.addEventListener("DOMContentLoaded", function () {
      const tooltips = document.querySelectorAll(".info-icon");

      document.addEventListener("click", function (event) {
        if (!event.target.closest(".info-icon")) {
          document
            .querySelectorAll(".info-icon.active")
            .forEach((activeIcon) => {
              activeIcon.classList.remove("active");
            });
        }
      });

      tooltips.forEach(function (icon) {
        let tooltip = icon.querySelector(".tooltip");
        if (!tooltip) {
          tooltip = document.createElement("div");
          tooltip.className = "tooltip";
          tooltip.textContent =
            icon.getAttribute("data-tooltip") || "Additional information";

          // Get positioning class from data attribute
          const positionClass =
            icon.getAttribute("data-tooltip-position") || "tooltip-center";
          tooltip.classList.add(positionClass);

          icon.appendChild(tooltip);
        }

        let isTooltipVisible = false;

        icon.addEventListener("click", function (event) {
          event.stopPropagation();

          document
            .querySelectorAll(".info-icon.active")
            .forEach((activeIcon) => {
              if (activeIcon !== icon) {
                activeIcon.classList.remove("active");
                const otherTooltip = activeIcon.querySelector(".tooltip");
                if (otherTooltip) otherTooltip.style.display = "none";
              }
            });

          isTooltipVisible = !this.classList.contains("active");
          this.classList.toggle("active");
          tooltip.style.display = isTooltipVisible ? "block" : "none";
        });
      });
    });
  </script>
</html>
